Paromomycin sulfate
ApprovedSmall molecule
Paromomycin sulfate is one of 45 small molecule programs targeting Cutaneous Leishmaniasis. It is currently in Approved.
3
Indications
7
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
56 competitors in Cutaneous Leishmaniasis
#DrugCompanyPhaseTrials
1Garamycin
SSchering-Plough
Approved
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Levaquin
WWim Janssens
Approved
Impavido
KKnight Therapeutics (USA) Inc
Phase 3
Meglumine Antimoniate
UUniversity of Brasilia
Approved
Pentam
FFresenius Kabi Oncology Ltd.
Phase 3
Aldara
BBausch Health Americas, Inc.
Phase 3
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Cipro
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Visceral Leishmaniasis3 trials
Cryptosporidiosis2 trials
Treatment of Chronic Cryptosporidiosis in AIDS Patients
Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001128·16 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Paromomycin sulfate. EMBL-EBI & Wellcome Sanger Institute.
- [4]